APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV Prevention Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global HIV Prevention Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025175 pages

Choose your research edition.

Industry ResearchHIV Prevention Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Prevention Drug Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal HIV Prevention Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Prevention Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Prevention Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global HIV Prevention Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for HIV Prevention Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of HIV Prevention Drug include Gilead Sciences and ViiV Healthcare among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global HIV Prevention Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV Prevention Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV Prevention Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the HIV Prevention Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

HIV Prevention Drug Segment by Company

Gilead Sciences

ViiV Healthcare

HIV Prevention Drug Segment by Type

Lenacapavir

Cabotegravir

HIV Prevention Drug Segment by Application

Hospital

Clinic

Others

HIV Prevention Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Prevention Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Prevention Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Prevention Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the HIV Prevention Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of HIV Prevention Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of HIV Prevention Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of HIV Prevention Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. HIV Prevention Drug Industry Trends Table 2. HIV Prevention Drug Industry Drivers Table 3. HIV Prevention Drug Industry Opportunities and Challenges Table 4. HIV Prevention Drug Industry Restraints Table 5. Global HIV Prevention Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global HIV Prevention Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global HIV Prevention Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global HIV Prevention Drug Sales Market Share by Manufacturers Table 9. Global HIV Prevention Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global HIV Prevention Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global HIV Prevention Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global HIV Prevention Drug Manufacturers, Product Type & Application Table 13. Global HIV Prevention Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global HIV Prevention Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lenacapavir Table 17. Major Manufacturers of Cabotegravir Table 18. Global HIV Prevention Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 20. Global HIV Prevention Drug Sales by Type (2027-2032) & (K Units) Table 21. Global HIV Prevention Drug Sales Market Share by Type (2021-2026) Table 22. Global HIV Prevention Drug Sales Market Share by Type (2027-2032) Table 23. Global HIV Prevention Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global HIV Prevention Drug Revenue by Type (2021-2026) & (K Units) Table 25. Global HIV Prevention Drug Revenue by Type (2027-2032) & (K Units) Table 26. Global HIV Prevention Drug Revenue Market Share by Type (2021-2026) Table 27. Global HIV Prevention Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Others Table 31. Global HIV Prevention Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 33. Global HIV Prevention Drug Sales by Application (2027-2032) & (K Units) Table 34. Global HIV Prevention Drug Sales Market Share by Application (2021-2026) Table 35. Global HIV Prevention Drug Sales Market Share by Application (2027-2032) Table 36. Global HIV Prevention Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global HIV Prevention Drug Revenue by Application (2021-2026) & (K Units) Table 38. Global HIV Prevention Drug Revenue by Application (2027-2032) & (K Units) Table 39. Global HIV Prevention Drug Revenue Market Share by Application (2021-2026) Table 40. Global HIV Prevention Drug Revenue Market Share by Application (2027-2032) Table 41. Global HIV Prevention Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global HIV Prevention Drug Sales by Region (2021-2026) & (K Units) Table 43. Global HIV Prevention Drug Sales Market Share by Region (2021-2026) Table 44. Global HIV Prevention Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global HIV Prevention Drug Sales Forecasted Market Share by Region (2027-2032) Table 46. North America HIV Prevention Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 48. North America HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 49. Europe HIV Prevention Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 51. Europe HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific HIV Prevention Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa HIV Prevention Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 58. Global HIV Prevention Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global HIV Prevention Drug Revenue by Region (2021-2026) & (US$ Million) Table 60. Global HIV Prevention Drug Revenue by Region (2027-2032) & (US$ Million) Table 61. Global HIV Prevention Drug Revenue Market Share by Region (2021-2026) Table 62. Global HIV Prevention Drug Revenue Market Share by Region (2027-2032) Table 63. Gilead Sciences Company Information Table 64. Gilead Sciences Business Overview Table 65. Gilead Sciences HIV Prevention Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Gilead Sciences HIV Prevention Drug Product Portfolio Table 67. Gilead Sciences Recent Development Table 68. ViiV Healthcare Company Information Table 69. ViiV Healthcare Business Overview Table 70. ViiV Healthcare HIV Prevention Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. ViiV Healthcare HIV Prevention Drug Product Portfolio Table 72. ViiV Healthcare Recent Development Table 73. Key Raw Materials Table 74. Raw Materials Key Suppliers Table 75. HIV Prevention Drug Distributors List Table 76. HIV Prevention Drug Customers List Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. HIV Prevention Drug Product Image Figure 2. Global HIV Prevention Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Prevention Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV Prevention Drug Sales (2021-2032) & (K Units) Figure 5. Global HIV Prevention Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 HIV Prevention Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lenacapavir Image Figure 9. Cabotegravir Image Figure 10. Global HIV Prevention Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global HIV Prevention Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global HIV Prevention Drug Sales Market Share by Type (2021-2032) Figure 13. Global HIV Prevention Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global HIV Prevention Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global HIV Prevention Drug Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global HIV Prevention Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global HIV Prevention Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global HIV Prevention Drug Sales Market Share by Application (2021-2032) Figure 22. Global HIV Prevention Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global HIV Prevention Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global HIV Prevention Drug Revenue Market Share by Application (2021-2032) Figure 25. North America HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America HIV Prevention Drug Sales Market Share by Country (2021-2032) Figure 27. U.S. HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe HIV Prevention Drug Sales Market Share by Country (2021-2032) Figure 32. Germany HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific HIV Prevention Drug Sales Market Share by Country (2021-2032) Figure 39. China HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa HIV Prevention Drug Sales Market Share by Country (2021-2032) Figure 47. Brazil HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile HIV Prevention Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global HIV Prevention Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global HIV Prevention Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Figure 58. North America HIV Prevention Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Figure 60. Europe HIV Prevention Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific HIV Prevention Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa HIV Prevention Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. HIV Prevention Drug Value Chain Figure 66. Manufacturing Cost Structure Figure 67. HIV Prevention Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Lenacapavir
  • Cabotegravir
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Gilead Sciences
  • ViiV Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HIV Prevention Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HIV Prevention Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global HIV Prevention Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global HIV Prevention Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global HIV Prevention Drug Market Dynamics
  1. 2.1 HIV Prevention Drug Industry Trends
  2. 2.2 HIV Prevention Drug Industry Drivers
  3. 2.3 HIV Prevention Drug Industry Opportunities and Challenges
  4. 2.4 HIV Prevention Drug Industry Restraints
3 HIV Prevention Drug Market by Manufacturers
  1. 3.1 Global HIV Prevention Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global HIV Prevention Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global HIV Prevention Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global HIV Prevention Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global HIV Prevention Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global HIV Prevention Drug Manufacturers, Product Type & Application
  7. 3.7 Global HIV Prevention Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global HIV Prevention Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 HIV Prevention Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 HIV Prevention Drug Tier 1, Tier 2, and Tier 3
4 HIV Prevention Drug Market by Type
  1. 4.1 HIV Prevention Drug Type Introduction
  2. 4.1.1 Lenacapavir
  3. 4.1.2 Cabotegravir
  4. 4.2 Global HIV Prevention Drug Sales by Type
  5. 4.2.1 Global HIV Prevention Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global HIV Prevention Drug Sales by Type (2021-2032)
  7. 4.2.3 Global HIV Prevention Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global HIV Prevention Drug Revenue by Type
  9. 4.3.1 Global HIV Prevention Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global HIV Prevention Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global HIV Prevention Drug Revenue Market Share by Type (2021-2032)
5 HIV Prevention Drug Market by Application
  1. 5.1 HIV Prevention Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global HIV Prevention Drug Sales by Application
  6. 5.2.1 Global HIV Prevention Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global HIV Prevention Drug Sales by Application (2021-2032)
  8. 5.2.3 Global HIV Prevention Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global HIV Prevention Drug Revenue by Application
  10. 5.3.1 Global HIV Prevention Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global HIV Prevention Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global HIV Prevention Drug Revenue Market Share by Application (2021-2032)
6 Global HIV Prevention Drug Sales by Region
  1. 6.1 Global HIV Prevention Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV Prevention Drug Sales by Region (2021-2032)
  3. 6.2.1 Global HIV Prevention Drug Sales by Region (2021-2026)
  4. 6.2.2 Global HIV Prevention Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HIV Prevention Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America HIV Prevention Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe HIV Prevention Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe HIV Prevention Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific HIV Prevention Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific HIV Prevention Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa HIV Prevention Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa HIV Prevention Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global HIV Prevention Drug Revenue by Region
  1. 7.1 Global HIV Prevention Drug Revenue by Region
  2. 7.1.1 Global HIV Prevention Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global HIV Prevention Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global HIV Prevention Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global HIV Prevention Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America HIV Prevention Drug Revenue (2021-2032)
  8. 7.2.2 North America HIV Prevention Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe HIV Prevention Drug Revenue (2021-2032)
  11. 7.3.2 Europe HIV Prevention Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific HIV Prevention Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific HIV Prevention Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa HIV Prevention Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa HIV Prevention Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Gilead Sciences
  2. 8.1.1 Gilead Sciences Company Information
  3. 8.1.2 Gilead Sciences Business Overview
  4. 8.1.3 Gilead Sciences HIV Prevention Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Gilead Sciences HIV Prevention Drug Product Portfolio
  6. 8.1.5 Gilead Sciences Recent Developments
  7. 8.2 ViiV Healthcare
  8. 8.2.1 ViiV Healthcare Company Information
  9. 8.2.2 ViiV Healthcare Business Overview
  10. 8.2.3 ViiV Healthcare HIV Prevention Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ViiV Healthcare HIV Prevention Drug Product Portfolio
  12. 8.2.5 ViiV Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 HIV Prevention Drug Value Chain Analysis
  2. 9.1.1 HIV Prevention Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 HIV Prevention Drug Production Mode & Process
  6. 9.2 HIV Prevention Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 HIV Prevention Drug Distributors
  9. 9.2.3 HIV Prevention Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst